SCHEMBL4868010

SCHEMBL4868010

COc1ccc(CNc2ncnc3ccccc23)cc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.78
STAT1 P42224 1/20 0.72
EGFR P00533 5/20 0.70
NR2F2 P24468 3/20 0.70
POLB P06746 1/20 0.70
BCHE P06276 4/20 0.65
ACHE P22303 4/20 0.65
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
HTT P42858 4/20 0.65
LMNA P02545 2/20 0.65
KDM4E B2RXH2 2/20 0.65
HPGD P15428 1/20 0.65
LCK P06239 1/20 0.64
PDE5A O76074 1/20 0.63
TNF P01375 1/20 0.63
NOD1 Q9Y239 1/20 0.63
ABCG2 Q9UNQ0 1/20 0.63
GALR3 O60755 2/20 0.62
RAB9A P51151 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16229848 0.89 EGFR (0.66) APPSTAT1EGFRNR2F2POLB
SCHEMBL17001434 0.88 APP (1.00) APPEGFRNR2F2POLBBCHE
SCHEMBL4867391 0.87 EGFR (0.67) APPSTAT1EGFRNR2F2POLB
SCHEMBL7500245 0.84 STAT1 (0.83) APPSTAT1EGFRMEN1KMT2A
SCHEMBL3112115 0.83 EGFR (1.00) APPEGFRNR2F2POLBMEN1
SCHEMBL4868121 0.82 MAPK1 (0.74) APPEGFRNR2F2POLBMEN1
SCHEMBL4074924 0.82 APP (0.67) APPSTAT1BCHEACHEMEN1
SCHEMBL4865169 0.82 EGFR (0.78) APPEGFRNR2F2POLBMEN1
SCHEMBL4859108 0.80 MAPK1 (0.76) EGFRNR2F2POLBMEN1KMT2A
SCHEMBL3121034 0.80 APP (0.79) APPSTAT1BCHEACHEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R APP 4386/4885STAT1 1088/4885EGFR 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.